Globus Medical, Inc. $GMED Stock Position Lowered by Fifth Third Bancorp

Fifth Third Bancorp trimmed its position in shares of Globus Medical, Inc. (NYSE:GMED) by 84.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,192 shares of the medical device company’s stock after selling 6,473 shares during the period. Fifth Third Bancorp’s holdings in Globus Medical were worth $68,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Paradice Investment Management LLC lifted its stake in Globus Medical by 20.9% in the 3rd quarter. Paradice Investment Management LLC now owns 663,038 shares of the medical device company’s stock worth $37,972,000 after acquiring an additional 114,433 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Globus Medical by 189.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 476,531 shares of the medical device company’s stock valued at $27,953,000 after acquiring an additional 312,149 shares in the last quarter. Foresight Group Ltd Liability Partnership increased its holdings in shares of Globus Medical by 160.7% in the 3rd quarter. Foresight Group Ltd Liability Partnership now owns 421,541 shares of the medical device company’s stock valued at $24,142,000 after purchasing an additional 259,870 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Globus Medical in the third quarter worth approximately $539,000. Finally, Lightrock Netherlands B.V. lifted its position in shares of Globus Medical by 6.2% in the third quarter. Lightrock Netherlands B.V. now owns 251,900 shares of the medical device company’s stock worth $14,426,000 after purchasing an additional 14,750 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Price Performance

NYSE GMED opened at $92.01 on Wednesday. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The stock’s 50-day moving average is $90.10 and its two-hundred day moving average is $75.84. The firm has a market cap of $12.31 billion, a P/E ratio of 29.68, a price-to-earnings-growth ratio of 1.43 and a beta of 1.06.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The business had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. During the same quarter in the prior year, the firm posted $0.84 EPS. The firm’s revenue for the quarter was up 25.7% on a year-over-year basis. On average, equities analysts expect that Globus Medical, Inc. will post 3.44 EPS for the current year.

More Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q4 revenue and adjusted results beat expectations — Globus reported Q4 net sales of $826.4M (+25.7% YoY) and strong adjusted EBITDA/non‑GAAP EPS, driven in part by the Nevro contribution and base business strength. GlobeNewswire Release
• Positive Sentiment: Raised non‑GAAP EPS guidance for 2026 and reconfirmed revenue range — management updated 2026 non‑GAAP EPS to $4.40–$4.50 and reaffirmed revenue of $3.18–$3.22B, signalling confidence in integration and margin leverage. Guidance / Release
• Positive Sentiment: Profitability expansion — company posted record non‑GAAP EPS and sizable increases in gross profit and operating profit, reflecting synergies from acquisitions and cost discipline. Quiver Quant Summary
• Neutral Sentiment: Investor materials and call scheduled — management held a conference call and published detailed GAAP/non‑GAAP reconciliations; listen/transcript available for further color on sustainability of margins. Press Release / Call Materials
• Neutral Sentiment: Wide analyst interest and price‑target dispersion — multiple firms maintain buy/overweight ratings with median targets near $100, but targets vary, so consensus reaction may diverge. Quiver – Analyst Snapshot
• Negative Sentiment: GAAP vs non‑GAAP earnings confusion — GAAP diluted EPS was $1.03 while non‑GAAP EPS was $1.28; some outlets reported an EPS “miss” on GAAP or different consensus metrics, creating headline risk and mixed press coverage. Quiver – EPS Detail
• Negative Sentiment: Growth concentrated in recent acquisitions — base business (ex‑Nevro) grew only ~5% for the year, raising questions about how much of future upside will rely on further M&A versus organic acceleration. Quiver – Business Mix
• Negative Sentiment: Cash and capital deployment concerns plus insider selling — cash and equivalents fell to ~$526M, capex and acquisitions were sizable, and recent insider sales were noted by data providers, which can pressure sentiment. Quiver – Cash & Insider Activity

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Needham & Company LLC upgraded shares of Globus Medical from a “hold” rating to a “buy” rating and set a $112.00 price objective on the stock in a research note on Friday, January 30th. BTIG Research restated a “neutral” rating on shares of Globus Medical in a report on Tuesday, December 30th. Barclays increased their price objective on Globus Medical from $106.00 to $114.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Piper Sandler reissued an “overweight” rating and set a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Finally, Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.18.

Insider Activity

In related news, EVP Kelly Huller sold 10,000 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $87.67, for a total value of $876,700.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kyle Kline sold 18,542 shares of Globus Medical stock in a transaction on Monday, December 1st. The stock was sold at an average price of $90.00, for a total transaction of $1,668,780.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 34,136 shares of company stock valued at $3,111,033 over the last 90 days. 18.54% of the stock is currently owned by company insiders.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.